Health-Related Quality of Life in PARP-Inhibitor Olaparib Maintenance in Ovarian Cancer Patients: Real World Data and Experience of a Single-Center in China

Objectives:To preliminarily explore the germline BRCA1/2 gene mutation status of patients with epithelial ovarian cancer (EOC), analyze the relationship with clinicopathological characteristics and the impact on survival and prognosis. Then examine the BRCA1/2 gene sequence mutation rate and the QOL of ovarian cancer patients with oral Olaparib in a single-center of China.Methods:A retrospective analysis of the survival and prognostic factors of 82 ovarian cancer patients who had undergone genetic testing in the Department of Gynecology, the First Affiliated Hospital of Nanjing Medical University from 2015 to 2018. These patients also underwent germline BRCA1/2 genetic testing. Then, we use the Quality of Life Questionnaire (QLQ-C30) and the Quality of Life Ovarian Cancer 28 Questionnaire (QLQ-OV28) to determine the relationship between quality of life (QOL) in each category, and key demographic and clinical factors.Results: The total mutation rate of BRCA1/2 was 30.48%, among which the pathogenic mutation rate of BRCA1 was 20.73%, and the pathogenic mutation rate of BRCA2 was 9.75% in our single-center. A total of 18 pathogenic mutation sites and 2 mutation sites of unknown significance were found. Olaparib as maintenance therapy was significantly associated with better QOL on all functioning domains and several symptom domains. The patients without Olaparib maintenance therapy may experience deteriorating QOL in several domains. Conclusions: Patients with EOC have a higher frequency of BRCA1/2 gene mutation rate, which is related to the malignant biological behavior of the tumor. Patients with BRCA1/2 gene mutation may have a better prognosis. Olaparib maintenance therapy is associated with better QOL and higher QOL in several domains in single center of Chinese.